Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

In vivo subcutaneous biocompatibility evaluation of decellularized tilapia fish skin in a rat model

Borra S., H K A., D'souza V., Shinde V., Sandhu JS., Pandey AK.

Animal Study on Chronic Wound, published in Sci Rep (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Sci Rep (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41168188
PMCID
PMC12575653
DOI
10.1038/s41598-025-21808-7
Citations
4

Abstract (original English)

Decellularized tilapia fish skin (DTFS) has emerged as a promising biocompatible implant for wound healing due to its high collagen content, retained extracellular matrix (ECM) components, and structural similarity to human skin. This study investigates the decellularization of tilapia fish skin using two protocols including sodium dodecyl sulfate and sodium chloride (Treatment 1) and Triton X-100 and sodium hydroxide (Treatment 2) and evaluates their efficacy and biocompatibility. Decellularization efficiency was assessed through DNA quantification, histological analysis, and scanning electron microscopy. The DNA content in DTFS was significantly reduced (8.65 ± 1.25 ng/mg in Treatment 1 and 18.05 ± 0.85 ng/mg in Treatment 2) compared to native tilapia fish skin (286 ± 11 ng/mg), confirming effective removal of cellular material. Structural integrity of ECM was preserved in both treatments. In vivo biocompatibility was assessed by implanting the native and DTFS subcutaneously in Wistar rats, followed by hematological, biochemical (Urea, ALT, ALP, and LDH), and histological analysis of skin and liver tissues over 28 days. No significant abnormalities were observed in serum parameters or tissue morphology, indicating high biocompatibility. These results support the potential use of DTFS which are biocompatible as viable wound dressing for burn and chronic wound applications.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Extracellular MatrixSkinAnimalsTilapiaRatsRats, WistarBiocompatible MaterialsMaterials TestingWound HealingMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research